In our case, the patient exhibited a notable clinical improvement primarily due to the administration of almonertinib, a third-generation EGFR-TKI, which underscores the potential efficacy of targeted therapy in managing ARDS secondary to advanced lung cancer. This evidence concerns the gene EGFR and lung carcinoma.